leisure time -WSS

leisure time

author：leisure time 2025-09-29 22:36:32 - browse：74715

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： What is STAT's opinion section for?

hotspot

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Healthy food access boosts outcomes in two studies

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

There’s a way to spot data fakery. All journals should be using it

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Telehealth startups are trying to fill the menopause care vacuum

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Weight loss drugs should be covered by insurers, AMA says

Virginia high school admissions case could be legal follow

Ohio still needs to do more to protect the right to abortion

Jerome Adams on the need for new antivirals for Covid

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Dementia risk linked to living in disadvantaged areas: Study

DIEP, the 'gold standard' of breast reconstruction, is under threat

Are infertility treatments 'essential' during the Covid

hotspot

NIH chief: government has fallen behind pharma on clinical trials

After decades in use, heart stents finally beat placebo

After decades in use, heart stents finally beat placebo

First transplant of an entire human eye performed

How a Boston hospital is priming medical residents to use GPT

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

focus

focus

hotspot

focus